Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Stephan A. Grupp(Children's Hospital of Philadelphia), Hidefumi Hiramatsu(Kyoto University), André Baruchel(Université Paris Cité), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Françoise Méchinaud(Hotel Dieu Hospital), Gary Douglas Myers(Baylor College of Medicine), Susana Rives(Hospital Sant Joan de Déu Barcelona), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Lamis Eldjerou, Shannon L. Maude(Children's Hospital of Philadelphia), Heather E. Stefanski(National Marrow Donor Program), Karen Thudium Mueller(Unknown), Joerg Krueger(Hospital for Sick Children), Barbara De Moerloose(Ghent University Hospital), Nicolas Boissel(Inserm), Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Gregory A. Yanik(University of Michigan), Jochen Büchner(Goethe University Frankfurt), Eric Bleickardt(Unknown), Theodore W. Laetsch(Children's Hospital of Philadelphia), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Paul L. Martin(Duke University), Michael W. Boyer(University of Utah), Mimi Leung(Unknown), Michael A. Pulsipher(Primary Children's Hospital), Lan Yi(Unknown), Kara L. Davis(Stanford Medicine)
Cited by 94
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867